The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: A pharmacological target for alternative therapy?

Calcified Tissue International

Volumn 71, Issue 4, 2002, Pages 293-299

  Teti, A ^b   Migliaccio, S ^b   Baron, R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

AlphaVbeta3 integrin; Cancer; Osteoclast; Osteolytic metastasis

Indexed keywords

ALPHA5 INTEGRIN; BETA3 INTEGRIN; FOCAL ADHESION KINASE 2; PROTEIN KINASE P60; PROTEIN SHC; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; VITRONECTIN RECEPTOR;

ANGIOGENESIS; BONE METASTASIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL SURVIVAL; ENDOTHELIUM CELL; HUMAN; MOLECULE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; BONE TUMOR; DRUG EFFECT; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; INTEGRIN ALPHAVBETA3; OSTEOCLASTS; OSTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 0036780593     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-001-2071-1     Document Type: Review

References (67)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
2. Liotta LA, Kohn EC (2001) The microenvironment of the tumor-host interface. Nature 411:375-379
3. Yoneda T (2000) Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75-81
4. Boyce BF, Yoneda T, Guise TA (1999) Factors regulating the growth of metastatic cancer in bone. Endocr Rel Cancer 34:333-337
5. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 15:1546-1556
6. Russell RGG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
7. Susa M, Glatt M, Teti A (2001) Tumor bone diseases: molecular mechanisms and opportunities for novel treatment. Curr Med Chem Anti-Cancer Agents 1:313-329
8. Diel IJ (2001) Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 28:75-80
9. Papapoulos SE, Hamdy NA, van der Pluijm G (2000) Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 88:3047-3053
10. Trypathy D (2001) Bisphosphonates in oncology: breast cancer and beyond. Semin Oncol 28:86-91
11. McCloskey EV, Guest JF, Kanis JA (2001) The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 61:1253-1274
12. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988
13. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA (2000) Integrins and signalling in osteoclast function. Matrix Biol 19:97-105
14. Roodman GD (2001) Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571
15. van der Pluijm G, Lowik C, Papapoulos S (2000) Tumor progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat Rev 26:11-27
16. Eliceiri BP, Cheresh DA (1999) The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227-1230
17. Penta K, Varner JA, Liaw L, Hidai C, Schatzman R, Quertermous T (1999) Dell induces integrin signaling and angiogenesis by ligation of αvβ3. J Biol Chem 274:11101-11109
18. Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8:724-730
19. Albelda SM, Mette SA, Elder DE, Stewart R, Damajanovich L, Herlyn M, Buck CA (1990) Integrin distribution in malignant melanoma: association of the beta3 subunit with tumor progression. Cancer Res 50:6757-6764
20. Liapis H, Flath A, Kitazawa S (1996) Integrin alphaVbeta3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 5:127-135
21. Sung V, Stubbs 3rd JT, Fisher L, Aaron AD, Thompson EW (1998) Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 176:482-494
22. v integrin cytoplasmic tail. J Biol Chem 271:31458-31462
23. Danen E, Jansen F, Van Kraatas A, Cornelissen I, Ruiter D, Van Miujen G (1995) AlphaV integrins in human melanoma: gain of alphaVbeta3 and loss of alphaVbeta3 are related to tumor progression in situ but not to metastastic capacity of cell lines in nude mice. Int J Cancer 61:491-496
24. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM (2001) Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 98:1853-1858
25. Sanders LC, Felding-Habermann B, Mueller BM, Cheresh DA (1992) Role of alphaV integrins and vitronectin in human melanoma cell growth. Cold Spring Harb Symp Quant Biol 58:233-240
26. Mitjans F, Sander D, Adan J, Sutler A, Martinez JM, Jaggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL (1995) An anti-alphaV-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 108:3067-3078
27. Mitjans F, Meyer T, Fittshen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J (2000) In vivo therapy of malignant melanoma by means of antagonists of alphaV integrins. Int J Cancer 87:716-723
28. Chatterjee N, Chatterjee A (2001) Role of alphaVbeta3 integrin receptor in the invasive potential of human cervical cancer (SiHa) cells. J Environ Pathol Toxicol Oncol 20:211-221
29. Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji M, Miwa A (2001) Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res 21:643-647
30. Montgomery AMP, Reisfeld RA, Cheresh DA (1993) Integrin alphaVbeta3 rescues melanoma from apoptosis in a three-dimensional dermal collagen. J Cell Biol 85:6792-6796
31. Townsend PA, Villanova I, Uhlmann E, Peyman A, Knolle J, Baron R, Teti A, Norton MA (2000) An antisense oligonucleotide targeting the αv integrin gene inhibits adhesion and induces apoptosis in breast cancer cells. Eur J Cancer 36:397-409
32. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA (1996) Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 15:426-433
33. Filardo EJ, Brooks PC, Deming SL, Cheresh DA (1995) Requirement of the NPXY motif in the integrin beta3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 130:441-450
34. Brooks PC, Stromblad S, Sanders L, Von Schalscha T, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alphaVbeta3. Cell 85:683-693
35. Van Waes C, Enamorado-Ayala I, Hecht D, Sulica L, Chen Z, Batt DG, Mousa S (2000) Effects of novel alphaV integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma RAM LY8. Int J Oncol 16:1189-1195
36. Aoki Y, Hosaka S, Kawa S, Kiyosawa K (2001) Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. Cancer Gene Ther 8:783-787
37. Horton MA (2001) Integrin antagonists as inhibitors of bone resorption: implications for treatment. Proc Nutr Soc 60:275-281
38. Van der Pluijm G, Vloedgraven HJ, Ivanov B, Robey FA, Grzesik WJ, Robey PG, Papapoulos SE, Lowik CW (1996) Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 56:1948-1955
39. Brooks PC, Clark RAF, Cheresh DA (1994) Requirement of vascular integrin alphaVbeta3 for angiogenesis. Science 264:569-571
40. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508
41. Roodman GA (1996) Advances in bone biology: the osteoclast. Endocr Rev 17:308-332
42. Marchisio PC, Naldini L, Cirillo D, Primavera MV, Teti A, Zambonin Zallone A (1984) Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures. J Cell Biol 99:1696-1705
43. Suda T, Nakamura I, Jimi E, Takanashi N (1997) Regulation of osteoclast function. J Bone Miner Res 12:869-879
44. v integrin synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis. J Bone Miner Res 14:1867-1879
45. Chellaiah M, Fitzgerald C, Alvarez U, Hruska K (1998) c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase. J Biol Chem 11908-11916
46. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702
47. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R (1996) c-cbl is downstream of c-src in a signaling pathway necessary for bone resorption. Nature 383:528-531
48. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda TF, Mundy GR, Boyce BF, Baron R, Teti A (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320
49. Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE (1997) Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mice. Genes Dev 11:2835-2844
50. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, Susa M (1999) A novel inhibitor of the tyrosine kinase Src suppressed phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437-449
51. Susa M, Teti A (2000) Tyrosine kinase Src inhibitors: potential therapeutic applications. Drug News Perspect 13:169-175
52. Ellis LM, Staley CA, Liu W, Declan Fleming RY, Parikh NU, Bucana CD, Gallick GE (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273:1052-1057
53. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src. J Biol Chem 274:25130-25135
54. Perez M, Migliaccio S, Taranta A, Festuccia C, Orru L, Brama M, Bologna M, Faraggiana T, Baron R, Teti A (2001) Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. Eur J Cancer 37:629-640
55. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028-1032
56. Luzi L, Confalonieri S, Di Fiore PP, Pelicci PG (2000) Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 10:668-674
57. Ravichandran KS (2001) Signaling via Shc family adapter proteins. Oncogene 20:6322-6339
58. Okada S, Kao AW, Ceresa BP, Blaikie P, Margolis B, Pessin JE (1997) The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. J Biol Chem 272:28042-28049
59. Chen KD, Li YS, Kim M, Li S, Yuan S, Chien S, Shyy JY-J (1999) Mechanotransduction in response to shear stress. Role of receptor tyrosine kinase, integrins, and Shc. J Biol Chem 274:18393-18400
60. Stevenson LE, Frackelton Jr AR (1998) Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression. Breast Cancer Res Treat 49:119-128
61. Jackson JG, Yoneda T, Clark GM, Yee D (2000) Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 6:1135-1139
62. Yang CP, Horwitz SB (2000) Taxol mediates serine phosphorylation of the 66-kDa Shc isoform. Cancer Res 60:5171-5178
63. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, Gailit J, Bowtell D, Home WC, Baron R (2001) Cbl associates with Pyk2 and Src to regulate Src kinase activity, alphaVbeta3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 152:181-195
64. Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, Zhang H, Baron R (2001) Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem 276:35182-35193
65. Sieg DJ, Ilic D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD (1998) PYK2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but PYK2 does not fully function to enhance FAK-cell migration. EMBO J 5933-5947
66. Blaukat A, Ivankovic-Dikic I, Gronroos E, Dolfi F, Tokiwa G, Vuori K, Dikic I (1999) Adaptor proteins Grb2 and Crk couple PYK2 with activation of specific mitogen-activated protein kinase cascades. J Biol Chem 274:14893-14901
67. Blaukat A, Ivankovic-Dikic I, Gronroos E, Dolfi F, Tokiwa G, Vuori K, Dikic I (1999) Adaptor proteins Grb2 and Crk couple PYK2 with activation of specific mitogena-ctivated protein cascades. J Biol Chem 274:14893-14901